Shannon H E, Lutz E A
Lilly Research Laboratories, Lilly Corporate Center, Indianapolis, USA.
Pain. 2000 Mar;85(1-2):161-7. doi: 10.1016/s0304-3959(99)00260-2.
Moxonidine is a mixed I(1) imidazoline/alpha(2)moxonidine=morphine. The I(1) imidazoline preferring antagonist efaroxan produced a dose-dependent antagonism of both moxonidine (5.0 mg/kg) and clonidine (0.5 mg/kg). In addition, the alpha(2)-adrenergic receptor antagonist yohimbine produced a dose-related antagonism of moxonidine, but only partially antagonized clonidine. Prazosin failed to block the effects of either moxonidine or clonidine, indicating a lack of involvement of alpha(1) as well as alpha(2B) and alpha(2C) receptors. The present results suggest that alpha(2)-adrenergic receptors play an important role in mediating the effects of moxonidine in producing antinociception in the formalin test. Further, the present results demonstrate that the mechanism of action of moxonidine and clonidine differ in that clonidine, but not moxonidine, produces an antinociceptive effect through a yohimbine-insensitive mechanism in the formalin test.
莫索尼定是一种混合型 I(1) 咪唑啉/α(2) 肾上腺素能受体激动剂,其抗伤害感受作用类似于吗啡。选择性 I(1) 咪唑啉拮抗剂依酚氯铵对莫索尼定(5.0 毫克/千克)和可乐定(0.5 毫克/千克)均产生剂量依赖性拮抗作用。此外,α(2) 肾上腺素能受体拮抗剂育亨宾对莫索尼定产生剂量相关的拮抗作用,但仅部分拮抗可乐定。哌唑嗪未能阻断莫索尼定或可乐定的作用,表明α(1) 以及α(2B) 和α(2C) 受体未参与其中。目前的结果表明,α(2) 肾上腺素能受体在介导莫索尼定在福尔马林试验中产生抗伤害感受作用方面发挥重要作用。此外,目前的结果表明,莫索尼定和可乐定的作用机制不同,因为在福尔马林试验中,可乐定通过一种育亨宾不敏感的机制产生抗伤害感受作用,而莫索尼定则不然。